OBJECTIVE: To determine the role of human papillomavirus (HPV) status on quality of life (QOL) in patients with oral cavity and oropharyngeal squamous cell carcinoma (OSCC). Since OSCC that are associated with high-risk HPV have an improved response to treatment and survival, we hypothesized that patients with these tumors would have better QOL trajectories. STUDY DESIGN: Prospective cohort study. SETTING: Tertiary care academic medical center and 2 affiliated hospitals. SUBJECTS AND METHODS: Head and neck-specific QOL was determined using the University of Washington Quality of Life scale version 4 in patients with newly diagnosed invasive OSSC (N = 228). RESULTS: Pretreatment QOL was higher in patients with high-risk HPV-associated tumors compared with patients with HPV-negative or low-risk HPV-associated tumors (P = .015). Patients with high-risk HPV-associated tumors had larger decreases in QOL from pretreatment to immediate posttreatment compared with patients with HPV-negative or low-risk HPV-associated tumors (P = .041). There was no association between HPV status and 1-year posttreatment QOL. CONCLUSION: Among OSCC patients, high-risk HPV-associated tumors were associated with higher pretreatment QOL and a larger decrease in QOL from pretreatment to immediate posttreatment, suggesting that treatment intensity in this unique population may adversely affect QOL.
OBJECTIVE: To determine the role of human papillomavirus (HPV) status on quality of life (QOL) in patients with oral cavity and oropharyngeal squamous cell carcinoma (OSCC). Since OSCC that are associated with high-risk HPV have an improved response to treatment and survival, we hypothesized that patients with these tumors would have better QOL trajectories. STUDY DESIGN: Prospective cohort study. SETTING: Tertiary care academic medical center and 2 affiliated hospitals. SUBJECTS AND METHODS: Head and neck-specific QOL was determined using the University of Washington Quality of Life scale version 4 in patients with newly diagnosed invasive OSSC (N = 228). RESULTS: Pretreatment QOL was higher in patients with high-risk HPV-associated tumors compared with patients with HPV-negative or low-risk HPV-associated tumors (P = .015). Patients with high-risk HPV-associated tumors had larger decreases in QOL from pretreatment to immediate posttreatment compared with patients with HPV-negative or low-risk HPV-associated tumors (P = .041). There was no association between HPV status and 1-year posttreatment QOL. CONCLUSION: Among OSCC patients, high-risk HPV-associated tumors were associated with higher pretreatment QOL and a larger decrease in QOL from pretreatment to immediate posttreatment, suggesting that treatment intensity in this unique population may adversely affect QOL.
Authors: Debbie J Horney; Helen E Smith; Mark McGurk; John Weinman; Jim Herold; Keith Altman; Carrie D Llewellyn Journal: Head Neck Date: 2011-01 Impact factor: 3.147
Authors: Pawadee Lohavanichbutr; John Houck; Wenhong Fan; Bevan Yueh; Eduardo Mendez; Neal Futran; David R Doody; Melissa P Upton; D Gregory Farwell; Stephen M Schwartz; Lue Ping Zhao; Chu Chen Journal: Arch Otolaryngol Head Neck Surg Date: 2009-02
Authors: Kathleen Settle; Marshall R Posner; Lisa M Schumaker; Ming Tan; Mohan Suntharalingam; Olga Goloubeva; Scott E Strome; Robert I Haddad; Shital S Patel; Earl V Cambell; Nicholas Sarlis; Jochen Lorch; Kevin J Cullen Journal: Cancer Prev Res (Phila) Date: 2009-07-29
Authors: Melina J Windon; Gypsyamber D'Souza; Farhoud Faraji; Tanya Troy; Wayne M Koch; Christine G Gourin; Ana P Kiess; Karen T Pitman; David W Eisele; Carole Fakhry Journal: Cancer Date: 2019-01-15 Impact factor: 6.860
Authors: M Vatca; J T Lucas; J Laudadio; R B D'Agostino; J D Waltonen; C A Sullivan; R Rouchard-Plasser; M Matsangou; J D Browne; K M Greven; M Porosnicu Journal: Oral Oncol Date: 2014-07-03 Impact factor: 5.337
Authors: Arun Sharma; Sapna Patel; Fred M Baik; Grant Mathison; Brendan H G Pierce; Samir S Khariwala; Bevan Yueh; Stephen M Schwartz; Eduardo Méndez Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-07-01 Impact factor: 6.223
Authors: Eleni M Rettig; Gypsyamber D'Souza; Carol B Thompson; Wayne M Koch; David W Eisele; Carole Fakhry Journal: Cancer Date: 2016-05-16 Impact factor: 6.860
Authors: R Alex Harbison; Mark Kubik; Eric Q Konnick; Qing Zhang; Seok-Geun Lee; Heuijoon Park; Jianan Zhang; Christopher S Carlson; Chu Chen; Stephen M Schwartz; Cristina P Rodriguez; Umamaheswar Duvvuri; Eduardo Méndez Journal: JCI Insight Date: 2018-07-26